Devyser Diagnostics AB (ST:DVYSR) — Market Cap & Net Worth
Market Cap & Net Worth: Devyser Diagnostics AB (DVYSR)
Devyser Diagnostics AB (ST:DVYSR) has a market capitalization of $168.47 Million (Skr1.57 Billion) as of May 2, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #17177 globally and #285 in its home market, demonstrating a 6.33% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Devyser Diagnostics AB's stock price Skr94.00 by its total outstanding shares 16653657 (16.65 Million). Analyse DVYSR operating cash flow to see how efficiently the company converts income to cash.
Devyser Diagnostics AB Market Cap History: 2021 to 2026
Devyser Diagnostics AB's market capitalization history from 2021 to 2026. Data shows growth from $158.79 Million to $168.47 Million (1.25% CAGR).
Index Memberships
Devyser Diagnostics AB is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
First North Sweden PI
FNSESEKPI
|
$14.99 Billion | 1.12% | #20 of 281 |
Weight: Devyser Diagnostics AB's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Devyser Diagnostics AB Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Devyser Diagnostics AB's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.98x
Devyser Diagnostics AB's market cap is 0.98 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $158.79 Million | $93.48 Million | -$20.73 Million | 1.70x | N/A |
| 2022 | $129.04 Million | $126.61 Million | -$45.95 Million | 1.02x | N/A |
| 2023 | $140.87 Million | $169.30 Million | -$53.60 Million | 0.83x | N/A |
| 2024 | $212.38 Million | $216.90 Million | -$61.50 Million | 0.98x | N/A |
Competitor Companies of DVYSR by Market Capitalization
Companies near Devyser Diagnostics AB in the global market cap rankings as of May 2, 2026.
Key companies related to Devyser Diagnostics AB by market ranking:
- Thermo Fisher Scientific Inc (NYSE:TMO): Ranked #126 globally with a market cap of $176.29 Billion USD.
- Danaher Corporation (NYSE:DHR): Ranked #189 globally with a market cap of $123.72 Billion USD.
- IDEXX Laboratories Inc (NASDAQ:IDXX): Ranked #578 globally with a market cap of $45.31 Billion USD.
- LONZA GROUP UNSP.ADR 1/10 (F:LO3A): Ranked #643 globally with a market cap of $41.04 Billion USD ( €35.10 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #126 | Thermo Fisher Scientific Inc | NYSE:TMO | $176.29 Billion | $469.21 |
| #189 | Danaher Corporation | NYSE:DHR | $123.72 Billion | $175.15 |
| #578 | IDEXX Laboratories Inc | NASDAQ:IDXX | $45.31 Billion | $567.46 |
| #643 | LONZA GROUP UNSP.ADR 1/10 | F:LO3A | $41.04 Billion | €54.50 |
Devyser Diagnostics AB Historical Marketcap From 2021 to 2026
Between 2021 and today, Devyser Diagnostics AB's market cap moved from $158.79 Million to $ 168.47 Million, with a yearly change of 1.25%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Skr168.47 Million | -17.69% |
| 2025 | Skr204.67 Million | -3.63% |
| 2024 | Skr212.38 Million | +50.76% |
| 2023 | Skr140.87 Million | +9.17% |
| 2022 | Skr129.04 Million | -18.74% |
| 2021 | Skr158.79 Million | -- |
End of Day Market Cap According to Different Sources
On May 2nd, 2026 the market cap of Devyser Diagnostics AB was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $168.47 Million USD |
| MoneyControl | $168.47 Million USD |
| MarketWatch | $168.47 Million USD |
| marketcap.company | $168.47 Million USD |
| Reuters | $168.47 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Devyser Diagnostics AB
Devyser Diagnostics AB (publ) engages in the development, manufacture, and sale of diagnostic kits and solutions for DNA testing within hereditary diseases, oncology, and post-transplantation monitoring in Sweden, rest of Europe, the Middle East, Africa, North and South America, and Asia. The company offers products in the areas of post-transplantation; thalassemia; breast, colorectal, and ovaria… Read more